Food Allergy Diagnostics & Therapeutics Market - Global Forecast 2025-2032

The Food Allergy Diagnostics & Therapeutics Market is evolving rapidly, driven by rising global prevalence, technological innovation, and diversification in both diagnostics and therapeutics. Senior decision-makers must navigate emerging complexities and identify opportunities in this dynamic sector to secure sustainable growth.

Market Snapshot: Food Allergy Diagnostics & Therapeutics Market

The Food Allergy Diagnostics & Therapeutics Market grew from USD 6.43 billion in 2024 to USD 7.14 billion in 2025. It is expected to continue growing at a CAGR of 10.75%, reaching USD 14.57 billion by 2032. This expanding market landscape is influenced by increasing allergy awareness, patient-centric initiatives, and a wave of technological advancements transforming point-of-care diagnostics and precision therapies. Stakeholders are adapting to new regulatory guidance, diversified reimbursement models, and a growing portfolio of diagnostic platforms and biologic treatments. As the market matures, actionable insight is essential for shaping investment and strategic direction.

Scope & Segmentation

This report provides in-depth analysis across the entire food allergy diagnostics and therapeutics value chain, including comprehensive segmentation and regional coverage. Key areas include:

• Product Types: Diagnostic Tests such as At-Home Allergy Tests, Component Resolved Diagnostics, Skin Prick Tests, and Specific IgE Tests; Therapeutic Products including Antihistamines, Emergency Treatments, Immunotherapy (Epicutaneous, Oral, Subcutaneous), and Monoclonal Antibodies.
• Allergen Types: Egg Allergy, Fish Allergy, Milk Allergy, Peanut Allergy, Sesame Allergy, Shellfish Allergy, Soy Allergy, Tree Nut Allergy, Wheat Allergy.
• End Users: Hospital Laboratories, Point-Of-Care Settings, Reference Laboratories, Research Institutes.
• Distribution Channels: Clinics & Diagnostic Centers, Hospitals, Online, Pharmacies.
• Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (with detailed subregions), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Leading Companies Analyzed: Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific SE, bioMérieux SA, Abbott Laboratories, Nestlé Health Science S.A., ALK-Abelló A/S, DBV Technologies S.A., Stallergenes Greer International S.A., and Aimmune Therapeutics LLC.

Key Takeaways for Strategic Decision-Makers

• Rapid technology adoption is advancing diagnostics with AI-driven analytics, microfluidics, and biosensors, enabling faster and more precise allergy profiling at the point of care.
• Integration between diagnostics and therapeutics is promoting patient-centric care models, with at-home and real-time monitoring platforms supporting personalized immunotherapy protocols.
• New treatment pathways are being pioneered through specialized immunotherapies and next-generation biologics, addressing both acute management and long-term tolerance to allergens.
• Market fragmentation is increasing, with emerging subsegments and new allergen types requiring tailored solutions and collaborative development among stakeholders.
• Strategies around digital transformation, telehealth, and unified data ecosystems are key for operational efficiency and expanded patient outreach across varied care settings.

Tariff Impact: Navigating Economic Shifts in the U.S. Sector

Recent tariff adjustments in the United States have intensified supply chain and procurement challenges, leading to increased costs for diagnostic reagents and advanced therapeutics. Manufacturers are compelled to diversify supplier networks, invest in domestic production, and advocate for regulatory relief to mitigate the impact of imposed tariffs. These dynamics influence clinical accessibility and escalate budget pressures across laboratories and care providers, making supply chain agility and policy engagement essential for continued innovation and patient access.

Research Methodology & Data Sources

This analysis integrates secondary research from peer-reviewed journals, regulatory bodies, and industry publications, with primary interviews involving industry experts, healthcare practitioners, and C-level executives. Inputs were triangulated using qualitative and quantitative analytical frameworks, with strict quality controls to ensure reliability. This robust methodology supports a comprehensive and actionable assessment of market opportunities and challenges.

Why This Report Matters

• Enables senior leaders to align R&D investment with specific clinical needs and evolving market dynamics.
• Delivers granular insights for refining product portfolios, regional strategies, and strategic partnerships across the care continuum.
• Supports risk mitigation and operational resilience planning amid shifting regulatory and economic conditions.

Conclusion

This report empowers decision-makers to address evolving complexities and seize emerging opportunities in food allergy diagnostics and therapeutics. Agile strategy, collaborative innovation, and continuous adaptation remain essential to driving value and enhancing patient outcomes in this dynamic sector.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.